0A45 Stock Chart & Stats
$148.30
$1.56(2.83%)
At close: 4:00 PM EDT
$148.30
$1.56(2.83%)
Day’s Range― - ―
52-Week Range$22.25 - $208.95
Previous CloseN/A
Volume42.49K
Average Volume (3M)253.81K
Market Cap
$81.23B
Enterprise Value$24.02K
Total Cash (Recent Filing)$5.14B
Total Debt (Recent Filing)$1.29B
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Oct 29, 2026EPS Estimate
-1.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.98
Shares Outstanding399,235,900
10 Day Avg. Volume91,518
30 Day Avg. Volume253,808
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.33
Price to Sales (P/S)5.90
P/FCF Ratio-5.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$110.44Price Target Upside-25.53% Downside
Rating ConsensusHold
Number of Analyst Covering20
EPS Forecast (FY)-8.32
Revenue Forecast (FY)$2.10B
Bulls Say, Bears Say
Bulls Say
Manageable Leverage And Substantial LiquidityLow-to-moderate leverage and substantial cash provide financial flexibility while Moderna funds research, manufacturing, and commercialization. This liquidity cushion can support pipeline investment and operational execution through a period of depressed profitability without relying solely on near-term operating cash generation.
Expanding Respiratory Vaccine PortfolioBroader respiratory approvals and procurement access reduce reliance on a single COVID product and create additional commercial opportunities across geographies. A wider portfolio can improve recurring seasonal demand, strengthen customer access, and provide a more durable foundation for future vaccine revenue.
Advancing Oncology And Rare-disease PipelineProgress across oncology and rare-disease programs demonstrates that Moderna is extending its mRNA platform beyond pandemic vaccines. Durable clinical validation and advancing late-stage studies could create new product categories, diversify future revenue, and increase the strategic value of its technology base.
Bears Say
Severe Profitability DeteriorationDeeply negative margins show that the current post-pandemic revenue base does not yet support Moderna’s cost structure. Continued operating losses can constrain investment choices, weaken returns on capital, and make recovery dependent on successful launches, materially limiting earnings durability.
Persistent Operating Cash BurnOngoing negative operating and free cash flow means the business is not currently self-funding its operations or pipeline. Continued cash consumption will gradually reduce financial flexibility, increasing reliance on existing liquidity, financing actions, or improved commercial performance to sustain development spending.
COVID Demand Decline And Product ConcentrationModerna remains exposed to a business mix historically dominated by COVID vaccine sales, a market where vaccination rates may decline. With certain products contributing no 2026 revenue under guidance, the company faces a transition risk while newer franchises and pipeline assets scale.
Moderna News
0A45 FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest share price was $22.25 and its highest was $208.95 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $81.23B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Oct 29, 2026 which is in 28 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Jul 31, 2026. The company reported -$1.97 earnings per share for the quarter, beating the consensus estimate of -$2.032 by $0.062.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Overvalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -1.1.
How many shares outstanding does Moderna have?
Moderna has 399,235,900 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$1.97 in its last earnings report, beating expectations of -$2.032. Following the earnings report the stock price went down -1.374%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in GB:0A45
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$110.44 (-25.53% Downside)
$110.44 (-25.53% Downside)
Blogger Sentiment
Neutral
GB:0A45 Sentiment 55%
Sector Average 65%
Sector Average 65%
News Sentiment
Bearish
Bullish news 22%
Bearish news 78%
Bearish news 78%
Technicals
SMA
Positive
20 days / 200 days
Momentum
645.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.73%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Moderna
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
0A45 Company Deck
0A45 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful commercial and clinical progress — a Q2 revenue beat, multiple regulatory and market milestones (including a VRBPAC recommendation for the flu candidate and expanded approvals for respiratory products), clear cost and efficiency improvements, and advancing oncology/rare disease programs with important data and new dosing initiatives. These positives were tempered by a norovirus Phase III interim that did not meet early success criteria and slower case accrual, a significant litigation settlement payment (~$950M) that reduced cash, a substantial net loss and continued cash burn, and timing uncertainty for several event‑driven readouts. On balance, the highlights (regulatory momentum, product approvals/market uptake, cost discipline and pipeline advances) modestly outweigh the lowlights, supporting a constructive but cautious outlook.View all GB:0A45 earnings summaries0A45 Revenue Breakdown
61.68% U.S.
2.73% Europe
35.60% Rest of World
0A45 Stock 12 Month Forecast
Average Price Target
$110.44
▼(-25.53% Downside)
Technical Analysis
Ionis Pharmaceuticals
―
Protagonist Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
―